FLT3 agonists and secondary hematopoietic malignancies: a potential class effect.
Henry W RaederMichael W DrazerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Expansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.
Keyphrases
- acute myeloid leukemia
- clinical trial
- allogeneic hematopoietic stem cell transplantation
- induced apoptosis
- tyrosine kinase
- cell cycle arrest
- case report
- bone marrow
- cell cycle
- open label
- signaling pathway
- cell death
- oxidative stress
- endoplasmic reticulum stress
- combination therapy
- risk assessment
- replacement therapy
- acute lymphoblastic leukemia
- climate change